|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: SYMBICORT
Summary for Tradename: SYMBICORT
|
|
Latest news for SYMBICORTIndependent Staff — Buy Tofranil Online Without Prescription » Online Pharmacy14 May 2013, 12:05 pm Buy Symbicort Online Without Prescription » Online Pharmacy14 May 2013, 12:05 pm Assessing Your Asthma is Key to Taking Control13 May 2013, 3:16 pm FDA approves Glaxo/Theravance drug for COPD lung disease10 May 2013, 1:33 pm US FDA approves Glaxo/Theravance drug for COPD lung disease10 May 2013, 1:32 pm Glaxo, Theravance Win Approval for Lung Disease Treatment10 May 2013, 12:59 pm Take a Deep Breath Before This Big FDA Decision5 May 2013, 2:59 pm AstraZeneca Earnings Tumble Y/Y26 April 2013, 12:20 pm Loss of exclusivity on several brands hurts AstraZeneca in Q125 April 2013, 3:01 am Courtesy of Yahoo News | ||||||||||
Clinical Trials for: SYMBICORTSymbicort Rapihaler Therapeutic Equivalence Study Status: Completed Condition: Bronchial Asthma A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma Status: Completed Condition: Asthma New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day Status: Completed Condition: Asthma Comparing Bronchodilation of Symbicort With and With Out Valved Holding Chamber (Aerochamber Plus) Status: Recruiting Condition: Asthma Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia Status: Completed Condition: Asthma Long-Term Safety of Symbicort in Asthmatic Children - SAPLING Status: Completed Condition: Asthma Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients Status: Completed Condition: Asthma Atlantis Symbicort Status: Completed Condition: Asthma Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Status: Recruiting Condition: Asthma Study to Investigate the Efficacy of Symbicort® SMART. Status: Completed Condition: Asthma Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | SYMBICORT | budesonide; formoterol fumarate dihydrate | AEROSOL, METERED; INHALATION | 021929 | Jul 21, 2006 | RX | Yes | 5,674,860 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | SYMBICORT | budesonide; formoterol fumarate dihydrate | AEROSOL, METERED; INHALATION | 021929 | Jul 21, 2006 | RX | Yes | 5,972,919 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | SYMBICORT | budesonide; formoterol fumarate dihydrate | AEROSOL, METERED; INHALATION | 021929 | Jul 21, 2006 | RX | Yes | 6,123,924 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | SYMBICORT | budesonide; formoterol fumarate dihydrate | AEROSOL, METERED; INHALATION | 021929 | Jul 21, 2006 | RX | Yes | 6,641,800 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc